



University of Colorado
Anschutz Medical Campus

Institutional Biosafety Committee (IBC)

Zoom Meeting Minutes

22 June 2026

9:00-11:00am (Mountain Time)

Attendance:

Voting IBC Members:

Dr. [REDACTED] (EC)
Dr. [REDACTED] (HD)
Dr. [REDACTED] (PD)**
Dr. [REDACTED] (MF)
Dr. [REDACTED] (LH)
Dr. [REDACTED] (BH)
Dr. [REDACTED] (SK)
Dr. [REDACTED] (AL)**
Dr. [REDACTED] (JL)
Dr. [REDACTED] (CM)
Dr. [REDACTED] (Co-chair) (BM)
Dr. [REDACTED] (MV)
[REDACTED] (ZJW)
[REDACTED] (ZW)

Non-voting IBC Members/Guests:

[REDACTED] (AA)
[REDACTED] (QB)
[REDACTED] (JW)
[REDACTED] (CW)*

I. Call to Order: 9:01am (Mountain Time)

II. Conflict of Interest:

- All present IBC members were reminded that no member of an IBC may be involved (except to provide information requested by the IBC) in the review of approval of a project in which he/she/they have been or expect(s) to have a conflict of interest—including financial interests, personal relationships, or involvement in the research. Any committee member with a conflict of interest shall abstain from the vote.

III. Review and Approval of Previous Minutes: 18 May 2026

The minutes were reviewed and approved by the IBC.

Approved = 14

Opposed = 0

Abstained = 0

IV. IBC Administrative Business:

A. IBC Administrative Changes: None

B. Protocol Closures:

- i. [REDACTED] - # 1245
- ii. [REDACTED] - # 24-2596

C. Protocol Transfers: None

Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:

During the review, the IBC assessed the containment levels in addition to the facilities, procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences, the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain



expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the *NIH Guidelines*.

V. New Business:

- 1. Environmental Health and Safety Office Updates:** None
- 2. Biosafety Office Updates:**
 - i. BH provided an update on the IBC protocol form migration process.

VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:

1. Patel, Sapna - # 25-2206: *Phase 1/2 study evaluating genetically modified autologous T cells expressing a T cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)*
2. Schenk, Erin - # 24-2314: *A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)*
3. McCandless, Shawn - # 23-2307: *A Phase I/II First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of a Single Intravenous (IV) Administration of ECUR-506 in Males Less than 9 Months of Age with Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency*
4. Macy, Margaret - # 24-1222: *NANT 2021-01: Phase II Study of Ex-vivo Expanded Allogeneic Universal Donor TgfB NK Cell Infusions in Combination with Temoxolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients with Relapsed or Refractory Neuroblastoma*
5. Schenk, Erin - # 24-2314: *A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)*
6. Kamdar, Manali - # 18-1632: *Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release*
7. Monge Urrea, Jorge - # 24-2523: *A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma*
8. Schenk, Erin - # 24-2314: *A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)*

VII. Clinical Trial (Human Gene Transfer) Protocol Reviews:

- 1. Schenk, Erin - # 26-0727: A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)**
Biosafety level: BSL-1 with standard precautions
NIH Section(s): III-C
Approved = 14
Opposed = 0
Abstained = 0



The IBC protocol presented was approved with the recommendation to address minor administrative items including selecting appropriate checkboxes and completing subsections for the IBC protocol application.

*CW left the meeting at 9:11am.

VIII. New Laboratory Protocol Reviews:

1. [REDACTED] - # 1771: **Characterizing and targeting intratumor heterogeneity in brain tumors (Previously deferred)**

Biosafety level: BSL-2, ABSL-2

NIH Section(s): III-D-4, III-D-2, III-D-1, III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation for modifications required to address updating details regarding the research narrative, BSC, material administration, IRB, PPE, and personnel.

IX. De Novo Laboratory Protocol Reviews:

1. [REDACTED] - # 1025: **Mechanisms of CD8+ T cell expansion and memory in response to immunization.**

Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2

NIH Section(s): III-D-1, III-D-2, III-D-3, III-D-4 III-E-1, III-E-3, III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation for modifications required to address updating details regarding the research narrative, animal use, BSC, PPE, and signs and symptoms for micro/infectious agents.

2. [REDACTED] - # 1147: **Gammaherpesviruses: acute and chronic infection and disease.**

Biosafety level: BSL-2, ABSL-2

NIH Section(s): III-D-4, III-E-1, III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including updating details regarding the NIH Guidelines, IBC protocol checkboxes, research narrative, procedures, and biomaterials.

3. [REDACTED] - # 1254: **Cancer progression and the tumor microenvironment.**

Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2

NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-E-3, III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including updating details regarding the research narrative, animal work, IBC protocol checkboxes, recombinant products, engineering controls, and overall IBC



protocol congruency.

4. [REDACTED] - # 1504: **Cerebellar circuit function**
Biosafety level: BSL-2, ABSL-2
NIH Section(s): III-D-4, III-D-1, III-E-1, III-F
Approved = 14
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating details regarding animal use, SA toxins including storage and disposal, BSC, import permits, and protocol attachments.
5. [REDACTED] - # 1451: **Dissection of how translational control regulates erythropoiesis.**
Biosafety level: BSL-1, BSL-2, ABSL-1
NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-F
Approved = 14
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating details regarding the research narrative, procedures, biosafety levels, agent table entries, and IBC protocol checkboxes.
6. [REDACTED] - # 1239: **Craniofacial morphogenesis and variability in zebrafish.**
Biosafety level: BSL-1, ABSL-1
NIH Section(s): III-D-4, III-F
Approved = 14
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating details regarding the research narrative, associated IACUC protocol expiration dates, IBC protocol checkboxes, NIH Guidelines, protocol attachments, and overall IBC protocol congruency.
7. [REDACTED] - # 1242: **Manipulation of exercise neural circuits**
Biosafety level: BSL-1, ABSL-1
NIH Section(s): III-D-4, III-F
Approved = 14
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating details regarding the research narrative, animal use, PPE, BSC, and protocol attachments.
8. [REDACTED] - # 1286: **Analysis of planar cell polarity (PCP) signaling in airway epithelial function**
Biosafety level: BSL-2, BSL-2+, ABSL-1
NIH Section(s): III-D-4, III-D-2, III-D-1, III-E-1, III-F
Approved = 14
Opposed = 0
Abstained = 0



The IBC protocol presented was approved with the recommendation for modifications required to address items including updating details regarding the research narrative, procedures, viral agents, and IBC protocol checkboxes.

9. [REDACTED] - # 1661: **The roles of granzymes and CD8 T cells in autoimmune disease**

Biosafety level: BSL-1, BSL-2, ABSL-1

NIH Section(s): III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including updating details regarding IBC protocol checkboxes, animal work, recombinant work, and procedures.

**AL and PD left the meeting at 10:37am.

10. [REDACTED] - # 1178: **Mechanisms and Therapeutics of Inflammation**

Biosafety level: BSL-1, BSL-2, ABSL-1

NIH Section(s): III-D-4, III-F

Approved = 14

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation for modifications required to address items including updating details regarding the research narrative, animal use, biosafety levels, recombinant products, micro/infectious agents, and procedures.

X. **Significant Amendment Reviews for Laboratory Protocols: None**

XI. **Exempt Protocols – New/Renewal:**

1. [REDACTED] - # 1776: *University of Colorado Skin Cancer Biorepository Core Protocol*
2. [REDACTED] - # 1777: *Characterizing the roles of chromatin modifiers in brain cancers*
3. [REDACTED] - # 1774: *Does sphingosine-1-phosphate impact bone remodeling upon semaglutide treatment in type 2 diabetes?*
4. [REDACTED] - # 1530: *Swanson Sleep-Bone Research*
5. [REDACTED] - # 1453: *Bone Biomechanics Research*
6. [REDACTED] - # 1503: *Association between Substance Use and Abuse with Development of Respiratory Conditions in Humans*
7. [REDACTED] - # 1080: *Mechanisms of Taste Cell Renewal*

XII. **Exempt Protocol Amendments:**

1. [REDACTED] - # 1264: *Investigations of bacterial species of interest and the further characterization of their genomes*
2. [REDACTED] - # 1616: *Investigating Molecular Mechanism of B-cell Acute Lymphoblastic Leukemia Pathogenesis and Immune Microenvironment interactions*
3. [REDACTED] - # 1238: *Understanding the biology and function of immune cells to improve outcomes after cancer and cellular therapy.*
4. [REDACTED] - # 1370: *Pre-clinical studies in rodent and miniature swine models to improve transplant outcomes*
5. [REDACTED] - # 1542: *Mechanisms of mRNA surveillance*



University of Colorado
Anschutz Medical Campus

6. [REDACTED] - # 1187: *Preparation of brain slices from naive rats and mice and rats subjected to early-life seizures*
7. [REDACTED] - # 1711: *The influence of blood product manufacturing and storage as it relates to transfusion efficacy and safety*

XIII. Additional Business: None

XIV. Next Meeting Scheduled: 27 July 2026, 9:00am (Mountain Time)

XV. Adjournment: 10:47am (Mountain Time)